A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1665
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : sGC
Long Form : soluble guanylate cyclase
No. Year Title Co-occurring Abbreviation
2021 A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. BP, cGMP
2021 Age-associated bladder and urethral coordination impairment and changes in urethral oxidative stress in rats. 8-OHdG, HIF-1alpha, MDA, NO, UPP
2021 Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits. ---
2021 An Analysis of the Multifaceted Roles of Heme in the Pathogenesis of Cancer and Related Diseases. Bach1, CBS, NOS, OXPHOS, PGRMC1
2021 C-type natriuretic peptide-induced relaxation through cGMP-dependent protein kinase and SERCA activation is impaired in two kidney-one clip rat aorta. cGMP, CNP, NO, NOS, pGC
2021 Carbon Monoxide-Releasing Molecule-3 Alleviates Kupffer Cell Pyroptosis Induced by Hemorrhagic Shock and Resuscitation via sGC-cGMP Signal Pathway. AST, CO, GSDMD, HSR, IL-1beta, TNF-alpha
2021 Characterization of endothelium-dependent and -independent processes in occipital artery of the rat: relevance to control of blood flow to nodose sensory cells. 5-HT, ACh, ECA, NG, OA
2021 Cinaciguat Prevents Postnatal Closure of Ductus Arteriosus by Vasodilation and Anti-remodeling in Neonatal Rats. Ang II, cGMP, DA, DASMCs, ROS
2021 Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. ERAs, NO, PAH, PDE5i
10  2021 Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. NO, PDEI
11  2021 Cyclic Guanosine Monophosphate Modulates Locomotor Acceleration Induced by Nitric Oxide but not Serotonin in Clione limacina Central Pattern Generator Swim Interneurons. cGMP, NO
12  2021 Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator. AG, IDT
13  2021 Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). ---
14  2021 Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension. IPAH, PDE5A, PKA
15  2021 Distinct Pharmacological Properties of Gaseous CO and CO-Releasing Molecule in Human Platelets. CO
16  2021 Downregulation of Soluble Guanylate Cyclase and Protein Kinase G With Upregulated ROCK2 in the Pulmonary Artery Leads to Thromboxane A2 Sensitization in Monocrotaline-Induced Pulmonary Hypertensive Rats. NO, PA, PAH, TXA2
17  2021 Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. HFrEF, NO, NT-proBNP
18  2021 Eriodictyol-Amplified 67-kDa Laminin Receptor Signaling Potentiates the Antiallergic Effect of O-Methylated Catechin. ASM, PCA
19  2021 Gaseous transmitter regulation of hypoxia-evoked catecholamine secretion from murine adrenal chromaffin cells. AMCs, CA, CO, CSE, HO, WT
20  2021 Higher susceptibility to heme oxidation and lower protein stability of the rare α1C517Yβ1 sGC variant associated with moyamoya syndrome. ---
21  2021 Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. CI, HF, HR, RCT
22  2021 Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step. NO
23  2021 Inflammation in the Human Periodontium Induces Downregulation of the α1- and β1-Subunits of the sGC in Cementoclasts. cGMP, NO
24  2021 Involvement of nNOS, and α1, α2, β1, and β2 Subunits of Soluble Guanylyl Cyclase Genes Expression in Anticonvulsant Effect of Sumatriptan on Pentylenetetrazole-Induced Seizure in Mice. cGMP, CST, nNOS, NO
25  2021 Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase. NO
26  2021 Mechanistic role of antioxidants in rescuing delayed gastric emptying in high fat diet induced diabetic female mice. CNM, CUR, DG, GE, HFD, NANC, ND, nNOSalpha, WT
27  2021 Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. CpcPH, EIPH, NFYA, PA, sGCbeta1
28  2021 Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices. NASH, PCLS
29  2021 Multidrug-resistant protein inhibitor and phosphodiesterase inhibitor potentiate the vasodilator effect induced by photobiomodulation in isolated aortic rings. NO, SNP
30  2021 Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. CKD, RBF
31  2021 Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease. SCD
32  2021 Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials. 6MWT, KCCQ, PLS
33  2021 Overexpression of GUCY1A2 Correlates With Poor Prognosis in Gastric Cancer Patients. GC, GSEA, NO, qRT-PCR
34  2021 Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO/sGC/cGMP pathway. 4-PBA, CADASIL, cGMP, eNOS, ER, GEFs, GOM, VSMCs
35  2021 Puerarin promotes the osteogenic differentiation of rat dental follicle cells by promoting the activation of the nitric oxide pathway. ALP, cGMP, DFCs, NO, OC, OPN, PKG-1, rDFCs
36  2021 Redox and Antioxidant Modulation of Circadian Rhythms: Effects of Nitroxyl, N-Acetylcysteine and Glutathione. AS, cGMP, NAC, SCN
37  2021 Regulatory effects of nitric oxide on reproduction and melanin biosynthesis in onion pathogenic fungus Stemphylium eturmiunum. c-PTIO, NO, SNP
38  2021 sGC Activity and Regulation of Blood Flow in a Zebrafish Model System. ---
39  2021 Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome. CD, cGMP, NO, SHR, SNP
40  2021 Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat. IUGR, RUPP
41  2021 Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis. PAH, SSc
42  2021 Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats. CNT, MCT, PAH, SIL, T4MN
43  2021 Soluble guanylate cyclase stimulators and their potential use: a patent review. ---
44  2021 Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation. cGMP, cryo-EM, NO
45  2021 Successful treatment of intravenous drug abuser with refractory vasoplegic syndrome after mitral valve repair for infective endocarditis. NO, NOS
46  2021 Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF-β Pathway. cGMP, DN, NPs, TGF-beta
47  2021 The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. cGMP, CNS, CSF, EEG, fMRI-BOLD, LTP, NMDA, NO
48  2021 The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction. GDMT, HFrEF, NO
49  2021 The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review. cGMP, DOX, PDEs, ROS
50  2021 Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet. AgRP, CNS, eNOS, GTPCH1, MBH, NPY, TBARS
51  2021 Vasorelaxant effect of water fraction of Labisia Pumila and its mechanisms in spontaneously hypertensive rats aortic ring preparation. cGMP, L-NAME
52  2021 Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. cGMP, HF, NO, WCHF
53  2021 Vericiguat: First Approval. NO
54  2021 Violet LED induces vasodilation in rat aortic rings by soluble guanylate cyclase-dependent mechanism and increases SOD activity. HUVEC, NO, SOD
55  2021 [Effects of electroacupuncture "Shuigou" on expression of soluble guanylate cyclase(sGC) and protein kinase G (PKG)in vascular smooth muscle of cerebral artery in rats with cerebral infarction]. CI, EA, PKG
56  2020 A Localized Scaffold for cGMP Increase Is Required for Apical Dendrite Development. cGMP, nNOS
57  2020 A new paradigm for gaseous ligand selectivity of hemoproteins highlighted by soluble guanylate cyclase. CO, NO
58  2020 A Surrogate Matrix-Based Approach Toward Multiplexed Quantitation of an sGC Stimulator and cGMP in Ocular Tissue and Plasma. cGMP
59  2020 An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling. HASMC
60  2020 Backbone and side chain NMR assignments of the H-NOX domain from Nostoc sp. in complex with BAY58-2667 (cinaciguat). NMR, NO
61  2020 BAY 41-2272 Attenuates CTGF Expression via sGC/cGMP-Independent Pathway in TGFbeta1-Activated Hepatic Stellate Cells. cGMP, HSCs, NO, TGF
62  2020 BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy. DOX, DOX-CM, ROS
63  2020 Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. SCA
64  2020 Bioactive Catalytic Nanocompartments Integrated into Cell Physiology and Their Amplification of a Native Signaling Cascade. cGMP, CNC, iNOS, NO
65  2020 Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation. CGRP, NO, RNOS, ROS
66  2020 Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. AMPK, PAH, PAMT, RVH, RVSP
67  2020 Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. ---
68  2020 Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. CaMKII, cGMP, DSS, ERK2, HFpEF, NO, PKG
69  2020 GAPDH delivers heme to soluble guanylyl cyclase. ---
70  2020 Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs. NO
71  2020 Indoxyl sulfate induces ROS production via the aryl hydrocarbon receptor-NADPH oxidase pathway and inactivates NO in vascular tissues. ACh, AhR, IS, NO, SNP
72  2020 Intrauterine growth restriction is associated with sex-specific alterations in the nitric oxide/cyclic GMP relaxing pathway in the human umbilical vein. AGA, cGMP, IBMX, IUGR, NO, PDEs, UV
73  2020 Mechanisms Associated to Nitroxyl (HNO)-Induced Relaxation in the Intestinal Smooth Muscle. ---
74  2020 Neisseria gonorrhoeae Blocks Epithelial Exfoliation by Nitric-Oxide-Mediated Metabolic Cross Talk to Promote Colonization in Mice. NO
75  2020 Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells. AMPK, HPASMC, NO, PDE3
76  2020 Nitric oxide: To be or not to be an endocrine hormone? NO
77  2020 Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease. NO
78  2020 Novel Barbiturate-Nitrate Compounds Inhibit the Upregulation of Matrix Metalloproteinase-9 Gene Expression in Intestinal Inflammation through a cGMP-Mediated Pathway. ---
79  2020 Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension. CTEPH, PAH, PH
80  2020 Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. iNO, LCPUFAs, PPARgamma, PPHN, PVR, rhVEGF
81  2020 Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. NO-cGMP, PDE5, PH
82  2020 Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. RPTCs
83  2020 Preserved activity of soluble guanylate cyclase (sGC) in iliac artery from middle-aged rats: Role of sGC modulators. ACh, IA, LUT, NO, ROS, SNP
84  2020 Riociguat ameliorates kidney injury and fibrosis in an animal model. CKD, RF, RIO, UUO
85  2020 Role of soluble guanylyl cyclase in renal afferent and efferent arterioles. AA, EA, NO, PDE5
86  2020 Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. CI, RCTs, RR
87  2020 Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma. NB, NO, OMS, PKG
88  2020 Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro. COX, eNOS, ET-1, HF, INDO, NE, Ser, SFI, Thr
89  2020 Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population. EH, HT, OR, preHT, SNPs
90  2020 Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds. cGMP, NO
91  2020 Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. BDL, CAB, CINA, IHVR, PDE, PHT, PSR, RIO, TADA, VEH
92  2020 Solution structures of the Shewanella woodyi H-NOX protein in the presence and absence of soluble guanylyl cyclase stimulator IWP-051. H-NOX, Sw
93  2020 Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia. H-FABP, IUGR, PE, RUPP, UARI
94  2020 Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit. IL, NASH, NF-kappaB, PKG, PRL, VASP
95  2020 Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling. LVM/BW, LVs
96  2020 Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. HFpEF, HFrEF, NO, NP, PDE
97  2020 The Possible Role of the Nitroso-Sulfide Signaling Pathway in the Vasomotoric Effect of Garlic Juice. ---
98  2020 Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclase. ---
99  2020 Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives. CTEPH, PAH, PDE5i, PEA, PH
100  2020 Tyrosine 135 of the β1 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugs. HNOX, NO